ASO Author Reflections: Annexin A3 as a Potential Biomarker for Hepatocellular Carcinoma

  • Xin-Rong YangEmail author
  • Wei GuoEmail author
ASO Author Reflections



The authors have no conflicts of interest to disclose.


  1. 1.
    Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835–53.CrossRefPubMedGoogle Scholar
  2. 2.
    Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844–55.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–22.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Ma XL, Jiang M, Zhao Y, et al. Application of serum annexin A3 in diagnosis, outcome prediction and therapeutic response evaluation for patients with hepatocellular carcinoma. Ann Surg Oncol. 2018;25:1686–94CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer InvasionMinistry of EducationShanghaiChina
  2. 2.Department of Laboratory Medicine, Zhongshan HospitalFudan UniversityShanghaiChina

Personalised recommendations